(Q39580436)

English

A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer.

scientific article published on 25 July 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22828917%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22828917%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22828917%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

author name string

Gary Hudes

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22828917%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Scott T Tagawa

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22828917%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Ming Qi

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22828917%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Xiang Qin

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22828917%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Thomas A Puchalski

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22828917%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Manjula Reddy

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22828917%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Mark Cornfeld

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22828917%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Mario Eisenberger

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22828917%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

publication date

25 July 2012

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22828917%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Investigational New Drugs

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22828917%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

31

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22828917%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

669-676

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22828917%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22828917%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

https://scigraph.springernature.com/pub.10.1007/s10637-012-9857-z

0 references

Interleukin-6 and prostate cancer progression

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9857-Z

21 January 2018

Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9857-Z

21 January 2018

The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9857-Z

21 January 2018

Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9857-Z

21 January 2018

Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9857-Z

21 January 2018

A rapid and sensitive liquid chromatography/tandem mass spectrometry method for determination of docetaxel in human plasma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9857-Z

21 January 2018

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9857-Z

21 January 2018

Clinical pharmacokinetics of docetaxel.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9857-Z

21 January 2018

Contribution of down-regulation of intestinal and hepatic cytochrome P450 3A to increased absorption of cyclosporine A in a rat nephrosis model

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9857-Z

21 January 2018

Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9857-Z

21 January 2018

A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9857-Z

21 January 2018

Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9857-Z

21 January 2018

Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor

1 reference

https://pubmed.ncbi.nlm.nih.gov/22828917

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22828917

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved

1 reference

https://pubmed.ncbi.nlm.nih.gov/22828917

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-012-9857-Z

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22828917%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22828917%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39580436&oldid=1856214115"